SEOUL, June 11 (Korea Bizwire) — Celltrion Inc., a South Korean biopharmaceutical firm, announced Thursday that it has signed an agreement to acquire the business rights for 18 brands of Takeda Pharmaceutical of Japan in the Asia-Pacific region. Under the 332.4 billion won (US$278.2 million) deal, Celltrion is set to secure the patent, trademark and [...]
SEOUL, June 10 (Korea Bizwire) — An affiliate of South Korean biopharmaceutical firm Celltrion Inc. said Wednesday that it will begin a study on the treatment efficacy of its biosimilar Remsima on the novel coronavirus. Celltrion Healthcare, which handles Celltrion’s overseas business, said the trial study of Remsima, a biosimilar drug to treat autoimmune diseases, [...]
SEOUL, June 1 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. announced Monday that positive results were shown for its treatment for the novel coronavirus in animal testing. The company said its antiviral antibody treatment showed a 100-fold reduction in the viral load of SARS-CoV-2, the virus known to be causing COVID-19, in an [...]
SEOUL, May 27 (Korea Bizwire) — South Korean pharmaceutical companies have joined the global race to develop a vaccine for the novel coronavirus, but none of them have received approval for clinical trials for a vaccine or treatment candidates from the country’s drug safety agency. Celltrion Inc., a major pharmaceutical giant, has announced that it [...]
SEOUL, March 23 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Monday that it is accelerating work on a treatment for the novel coronavirus as part of its efforts to address the global pandemic. The company was earlier selected as a preferred developer for a monoclonal antibody project to treat and prevent COVID-19 [...]
SEOUL, Jan. 21 (Korea Bizwire) — Major South Korean biosimilar manufacturer Celltrion Inc. said Tuesday it will spend 600 billion won (US$520 million) on its new plant in China over the next five years. The planned plant, with a production capacity of 120,000 liters of biopharmaceutical products, will be located in the central city of [...]
SEOUL, Jan. 16 (Korea Bizwire) — Major South Korean biosimilar manufacturer Celltrion Inc. plans to build a plant in China in a move to directly advance into the world’s second-largest biopharmaceutical market, its chief said. “We are in the final stage of signing a contract with the Chinese government. We will soon announce details of [...]
SEOUL, May 16 (Korea Bizwire) — Celltrion Inc. will invest 40 trillion won (US$33.7 billion) and create 110,000 jobs by 2030 as the South Korean biosimilar firm moves to take a leap forward as a global player, the company’s chairman said Thursday. The company’s business roadmap centers on cooperating with local governments to make the [...]
SEOUL, Apr. 27 (Korea Bizwire) — South Korea’s pharmaceutical giant Celltrion has become a strong competitor to European and U.S. drugs with its biosimilars, indicated by changes in sales, industry officials said Friday. Multinational drugmaker Roche logged a 44 percent fall in sales of Mabthera, an antibody used to treat rheumatoid arthritis, lymphoma and some [...]
SEOUL, March 28 (Korea Bizwire) — An affiliate of South Korean biopharmaceutical firm Celltrion Inc. said Wednesday that the market share of the biosimilar drug Remsima came to 52 percent in Europe during the fourth quarter of last year. The market share of Remsima surpassed that of its original drug, Remicade, by Janssen Biotech, Inc., [...]